The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs

Brian Strom, Jeffrey Carson, M. Lee Morse, M. Lee West, Keith A. Soper

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

A large, computerized database derived from Medicaid claims was used to evaluate the risk of allergy and/or anaphylaxis associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs) as a class and the risk associated with the use of zomepirac relative to other NSAIDs. We compared 51,797 patients exposed to NSAIDs with 35,634 age‐ and sex‐matched patients who had not been exposed. As a class, NSAIDs were associated with an adjusted relative risk (95% confidence interval) of hypersensitivity reactions of 2.0 (1.3–2.9). The increased risk was accentuated in those with a diagnosis compatible with acute pain (3.6 [2.2–5.9]) and absent in those without such a diagnosis (1.1 [0.6–1.9]). Comparison of those exposed to zomepirac with those exposed to other NSAIDs resulted in an age‐adjusted relative risk of 2.0 (1.1–4.7). Stratification by the probable indication for NSAID use again suggested that the risk may be explained by the use of the NSAIDs for different indications. We concluded that NSAIDs are associated with an increased risk of allergy and/or anaphylaxis, and the use of zomepirac appears to be associated with an increased risk compared with the use of other NSAIDs. However, that increased risk may be a function of the primary indication for the drug or, more likely, the regimen associated with that indication, rather than an intrinsic property of the drug.

Original languageEnglish (US)
Pages (from-to)1142-1148
Number of pages7
JournalArthritis & Rheumatism
Volume30
Issue number10
DOIs
StatePublished - Jan 1 1987

Fingerprint

Hypersensitivity
Anti-Inflammatory Agents
Pharmaceutical Preparations
Anaphylaxis
zomepirac
Medicaid
Acute Pain
Databases
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

@article{817e5984809a4192a003bab7a71b5832,
title = "The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs",
abstract = "A large, computerized database derived from Medicaid claims was used to evaluate the risk of allergy and/or anaphylaxis associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs) as a class and the risk associated with the use of zomepirac relative to other NSAIDs. We compared 51,797 patients exposed to NSAIDs with 35,634 age‐ and sex‐matched patients who had not been exposed. As a class, NSAIDs were associated with an adjusted relative risk (95{\%} confidence interval) of hypersensitivity reactions of 2.0 (1.3–2.9). The increased risk was accentuated in those with a diagnosis compatible with acute pain (3.6 [2.2–5.9]) and absent in those without such a diagnosis (1.1 [0.6–1.9]). Comparison of those exposed to zomepirac with those exposed to other NSAIDs resulted in an age‐adjusted relative risk of 2.0 (1.1–4.7). Stratification by the probable indication for NSAID use again suggested that the risk may be explained by the use of the NSAIDs for different indications. We concluded that NSAIDs are associated with an increased risk of allergy and/or anaphylaxis, and the use of zomepirac appears to be associated with an increased risk compared with the use of other NSAIDs. However, that increased risk may be a function of the primary indication for the drug or, more likely, the regimen associated with that indication, rather than an intrinsic property of the drug.",
author = "Brian Strom and Jeffrey Carson and Morse, {M. Lee} and West, {M. Lee} and Soper, {Keith A.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1002/art.1780301009",
language = "English (US)",
volume = "30",
pages = "1142--1148",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs. / Strom, Brian; Carson, Jeffrey; Morse, M. Lee; West, M. Lee; Soper, Keith A.

In: Arthritis & Rheumatism, Vol. 30, No. 10, 01.01.1987, p. 1142-1148.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs

AU - Strom, Brian

AU - Carson, Jeffrey

AU - Morse, M. Lee

AU - West, M. Lee

AU - Soper, Keith A.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - A large, computerized database derived from Medicaid claims was used to evaluate the risk of allergy and/or anaphylaxis associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs) as a class and the risk associated with the use of zomepirac relative to other NSAIDs. We compared 51,797 patients exposed to NSAIDs with 35,634 age‐ and sex‐matched patients who had not been exposed. As a class, NSAIDs were associated with an adjusted relative risk (95% confidence interval) of hypersensitivity reactions of 2.0 (1.3–2.9). The increased risk was accentuated in those with a diagnosis compatible with acute pain (3.6 [2.2–5.9]) and absent in those without such a diagnosis (1.1 [0.6–1.9]). Comparison of those exposed to zomepirac with those exposed to other NSAIDs resulted in an age‐adjusted relative risk of 2.0 (1.1–4.7). Stratification by the probable indication for NSAID use again suggested that the risk may be explained by the use of the NSAIDs for different indications. We concluded that NSAIDs are associated with an increased risk of allergy and/or anaphylaxis, and the use of zomepirac appears to be associated with an increased risk compared with the use of other NSAIDs. However, that increased risk may be a function of the primary indication for the drug or, more likely, the regimen associated with that indication, rather than an intrinsic property of the drug.

AB - A large, computerized database derived from Medicaid claims was used to evaluate the risk of allergy and/or anaphylaxis associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs) as a class and the risk associated with the use of zomepirac relative to other NSAIDs. We compared 51,797 patients exposed to NSAIDs with 35,634 age‐ and sex‐matched patients who had not been exposed. As a class, NSAIDs were associated with an adjusted relative risk (95% confidence interval) of hypersensitivity reactions of 2.0 (1.3–2.9). The increased risk was accentuated in those with a diagnosis compatible with acute pain (3.6 [2.2–5.9]) and absent in those without such a diagnosis (1.1 [0.6–1.9]). Comparison of those exposed to zomepirac with those exposed to other NSAIDs resulted in an age‐adjusted relative risk of 2.0 (1.1–4.7). Stratification by the probable indication for NSAID use again suggested that the risk may be explained by the use of the NSAIDs for different indications. We concluded that NSAIDs are associated with an increased risk of allergy and/or anaphylaxis, and the use of zomepirac appears to be associated with an increased risk compared with the use of other NSAIDs. However, that increased risk may be a function of the primary indication for the drug or, more likely, the regimen associated with that indication, rather than an intrinsic property of the drug.

UR - http://www.scopus.com/inward/record.url?scp=0023572352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023572352&partnerID=8YFLogxK

U2 - 10.1002/art.1780301009

DO - 10.1002/art.1780301009

M3 - Article

C2 - 3314878

AN - SCOPUS:0023572352

VL - 30

SP - 1142

EP - 1148

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 10

ER -